Summit Trail Advisors’s Avanos Medical AVNS Stock Holding History

Summit Trail Advisors’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-16	Closed	-$1K	–	530
2017 Q4	$1K	Buy	+16	New	+$735	﹤0.01%	1752

Other funds holding AVNS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CCM

Channing Capital Management Chicago, Illinois $4.34B AUM 37.08% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Summit Trail Advisors's AVNS Position: Q1 2018 in Review

Summit Trail Advisors sold out of Avanos Medical (AVNS) in Q1 2018, closing a stake of 16 shares — an estimated $1K sold.

Summit Trail Advisors first reported a position in AVNS in Q4 2017 and held it in 1 quarter. The position peaked at $1K in Q4 2017. 338 funds tracked by Wall St. Rank hold AVNS as of Q1 2018.

Summit Trail Advisors reported no remaining Avanos Medical position as of Q1 2018 after selling out during the quarter.
Summit Trail Advisors sold 16 Avanos Medical shares in Q1 2018, an estimated $1K.
Summit Trail Advisors first reported a position in Avanos Medical in Q4 2017 and held it in 1 quarter.
Summit Trail Advisors's Avanos Medical position peaked at $1K in Q4 2017.
338 funds tracked by Wall St. Rank held Avanos Medical as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.